Syngene reports Q1 FY26 revenue higher at Rs. 875 Cr

Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%

Lonza reports 19% growth in sales in H1

Upgrades 2025 full-year CDMO sales and margin outlook

Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr

During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D

Sigachi Industries FY25 revenue surges 25%, EBITDA 46%

Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients

SeQuent–Viyash merger receives stock exchange approvals; NCLT filing underway

Alkem reports 7.1% YoY revenue growth in Q4 FY25

Annual EBITDA margin expands by 170 basis points

Sanjivani Paranteral posts Q4 FY25 at Rs. 2.19 Cr

For FY25, Revenue from operation grew 28.8 per cent YoY to Rs. 70.1 crore

Sun Pharma Q4 FY25 revenue up 8.5% to Rs. 12,815 Cr

Net profit for the?quarter came in at Rs. 2,889.1 crore, up 4.8 per cent from the year earlier, adjusted for exceptional items

Akums reports Q4 FY25 with 12.4% revenue growth

Akums invested Rs. 272 crore in capital expenditure during FY25

Gland Pharma Q4 FY25 PAT falls to Rs. 186.5 Cr

R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue